“We are excited about this partnership as it paves the way for us to bring quality paediatric formulations to the growing needs of patients in China. In addition to marketing our paediatric products in the Chinese market, we intend to expand our collaboration in other strategic therapeutics areas such as cardiometabolic, central nervous system and gastro-enterology.” - Dr. Fabrice Egros, President - Corporate Development and Growth Markets, Lupin
May 2022 : Global pharma major Lupin Limited (Lupin) has recently announced that it has entered into a strategic partnership with Yabao Pharmaceutical Co. Inc. (Yabao), to meet the growing demand for quality drugs with paediatric formulations in the Chinese markets.
The demand for high quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures. The latest Chinese paediatric pharmaceutical market report indicates that the market for paediatric drugs in China is expected to reach 210 billion CNY (33 billion US$) in 2021, growing at a rate of 9.23%.
Dr. Fabrice Egros, President - Corporate Development and Growth Markets, Lupin said, “We are excited about this partnership as it paves the way for us to bring quality paediatric formulations to the growing needs of patients in China. In addition to marketing our paediatric products in the Chinese market, we intend to expand our collaboration in other strategic therapeutics areas such as cardiometabolic, central nervous system and gastro-enterology.”
Wei Ren, President of Yabao said, “We are very pleased to be partnering with Lupin to further strengthen Yabao’s leadership position in the paediatric market. Yabao strives to develop its paediatric pipeline to address the urgent unmet needs in the market and to serve the paediatric patients. Moreover, Yabao also looks forward to expanding the collaboration with Lupin in other areas.”
About Lupin: Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue in research and development in FY21. Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
NEWSLETTER
TRENDING ON PRO MFG
MORE FROM THE SECTION
